LOC729460 Inhibitors

LY294002 and Wortmannin are both inhibitors of PI3K, which is pivotal in the PI3K/AKT pathway, a critical regulator of cellular functions such as growth, metabolism, and survival. The inhibition of this pathway can lead to reduced activity of downstream effectors, possibly impacting LOC729460 if it is a downstream target. Rapamycin specifically inhibits mTOR, a central component in cell growth and proliferation, and its inhibition can have far-reaching effects on cellular processes.

PD98059 and U0126 both target MEK, a key enzyme in the MAPK/ERK pathway, which plays a critical role in cell division and differentiation. SP600125 and SB203580 inhibit JNK and p38 MAPK, respectively, both of which are involved in cellular responses to stress and inflammation. These inhibitors can modify the cellular environment, potentially affecting the stability or activity of LOC729460. PP2 and Ibrutinib target kinases involved in cell signaling related to growth, differentiation, and survival. ZM-447439 disrupts cell cycle progression by inhibiting Aurora kinases, which are essential for mitotic spindle assembly. BML-275 targets AMPK, a regulator of energy homeostasis, and Thapsigargin disrupts calcium homeostasis by inhibiting the SERCA pump, potentially affecting numerous calcium-dependent processes.